Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

Protective Immune Responses" was published online in PloS ONE.

Animal Health

  • The Company's foot-and-mouth disease (FMD) vaccine for use in cattle received a conditional license from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS), which provides that the product may be distributed as authorized by Federal emergency management officials within USDA, should the need for the product arise.  This is GenVec's first approved product and also the first FMD vaccine licensed by the USDA Center for Veterinary Biologics. 
  • 2012 Financial ResultsRevenue decreased 47% to $9.4 million in 2012 from $17.7 million in 2011.  The decrease in 2012 is primarily due to decreased revenue of $5.6 million, $1.5 million, and $1.2 million generated by our hearing loss and balance disorders, HIV, and foot and mouth disease programs, respectively, over the prior year.  We entered into a collaboration agreement with Novartis in January 2010, which accounted for $0.9 million and $3.8 million of revenue in 2012 and 2011, respectively, and a development agreement related to the supply of clinical trial material related to activities under the collaboration agreement in August 2010, which accounted for $3.5 million and $6.0 million in revenue in 2012 and 2011, respectively.  A reduced work scope as we near completion of our development work under the two Novartis agreements resulted in decreased revenue in 2012 as compared to 2011.  Decreased revenue associated with our foot and mouth disease program is due mainly to a decrease in work scope and the successful completion of field safety studies under our agreements with the Department of Homeland Security (DHS).  Decreased revenue associated with our HIV program as compared to the prior year is due to reduced work scope.

    Operating expenses for 2012 decreased 7% to $23.5 million from $25.2 million in 2011.  Research and development expense
    '/>"/>

    SOURCE GenVec, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
    2. GenVec Appoints Cynthia Collins as President and CEO
    3. GenVec Reports Inducement Award
    4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
    5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
    6. GenVec Reports Second Quarter 2012 Financial Results
    7. GenVec Reports Third Quarter 2012 Financial Results
    8. GenVec to Present at 25th Annual ROTH Conference
    9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... , Sept. 2, 2015 Research and Markets ( ... Regulatory Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... will provide a detailed overview of the key areas of ... Hong Kong , Macau ... - All important aspects of gaining and maintaining ...
    (Date:9/2/2015)... Miss. , Sept. 2, 2015   Gulf Coast Tattoo ... removal services with the cutting-edge Astanza Duality laser in ... unwanted ink erase their tattoo regret and take back control of ... but extends its services to Biloxi ... region. "With tattoo regret being as prevalent as it ...
    (Date:9/2/2015)... , Sept. 2, 2015  Research and Markets ... the "An Introduction to the Medical Devices ... conference to their offering. This ... medical device legislation. It will explain the Directives ... Notified Bodies, how to choose one and outline ...
    Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2
    ... BETHESDA, Md. , Aug. 2 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") ... of Western,healthcare products and services in the People,s Republic of China ... results on Monday, August 9, 2010 , before the market opens.,Management ... day to discuss,financial results. , , ...
    ... PALO ALTO, Calif. , Aug. 2 Jazz Pharmaceuticals, Inc. (Nasdaq: ... 2010 financial results on Tuesday, August 10, 2010 .  Jazz Pharmaceuticals will host ... as to discuss financial results and guidance, on August 10, 2010 , at ... , , ...
    Cached Medicine Technology:Chindex International to Report First Quarter 2011 Financial Results 2Jazz Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 10 2
    (Date:9/2/2015)... , ... September 03, 2015 , ... ... and frequently listed among the most influential leaders in healthcare, will offer the ... Coalition, to take place October 15-16, 2015, in Palm Harbor, Florida, at the ...
    (Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
    (Date:9/2/2015)... ... ... Sara Bleich, Ph.D., associate professor of health and policy ... recognized scholar on obesity prevention and control, has been selected for the prestigious ... graduate of Garrison Forest School, an all-girls’ independent school in Owings Mills, Md., ...
    (Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
    (Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system ... complex of the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or ... of any given guide RNA (sgRNA or crRNA) to create a break in the ...
    Breaking Medicine News(10 mins):Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4
    ... , , , ANNAPOLIS, ... PIP ), a biodefense company developing medical countermeasures against biological ... agreements for the issuance of 2-year, 10% unsecured senior convertible ... private placement of approximately $19.3 million. , , ...
    ... July 27 Health Robotics today announced,that it has ... to market,implement, and support its I.V. Workflow Engine and ... North America. One of,its software modules (OncoCube) has already ... University of Colorado Hospital [Denver], in,addition to all-digital ...
    ... , , , ... reveals that adults living in the country,s fifth largest city are ... and complex conditions. Many commonly used therapy classes including drugs to ... have experienced increases in adults 20 and older. , ...
    ... , Trinitas Comprehensive Cancer Center in Elizabeth, ... chemotherapy program in place , , LOS ... a variety of cancers--along with projections from the National Comprehensive Cancer Network ... by 2013--raise questions for both clinicians and patients with regard to the ...
    ... COLD SPRING HARBOR, N.Y., July 27 AccuVein LLC, ... illumination device, today announced that its quality system has received ... to customers around the globe AccuVein,s commitment to the quality ... and delivery procedures. , , ...
    ... , FRANKLIN, Mass., July 27 PLC ... innovative cardiac and vascular medical device-based technologies, today announced it ... capabilities provided by RenalGuard(R) from the Canadian Intellectual Property Office ... patent for RenalGuard in Canada. , , ...
    Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 2Health News:Health Robotics Announces American Joint Venture With i.v.SOFT 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 2Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 3Health News:Chronic and Complex Diseases on the Rise in Philadelphia: Adults Using More Medications to Treat Chronic Conditions 4Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 2Health News:Oral Chemotherapy Offers Patients a More Convenient, Less Invasive Treatment Option 3Health News:AccuVein Achieves Quality System Milestone 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2
    RCB™ Rotator Cuff Buttress is a completely resorbable plate that will alleviate suture migration in open or mini-Open rotator cuff repairs....
    ... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
    ... an absorbable co-polymer synthesized from all-natural ... glycolic acid. Unlike the homopolymers in ... acid (PLLA) or 100% poly-glycolic acid ... (without crystallinity), meaning that its degradation ...
    ... Medicine™ AnchorSew™ 3 mm is a resorbable repair ... Medicine ArthroSew suturing device to attach soft tissue ... implanted into a prepared hole in the bone, ... soft tissue anchors are made of a resorbable ...
    Medicine Products: